Myriad Genetics (MYGN) Total Liabilities (2010 - 2026)

Myriad Genetics (MYGN) has 17 years of Total Liabilities data on file, last reported at $336.3 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $336.3 million, up 11.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $336.3 million (up 11.65% YoY), and the FY2025 annual result was $338.6 million, up 3.71% from the prior year.
• Total Liabilities eased to $336.3 million in Q1 2026 per MYGN's latest filing, from $338.6 million in the prior quarter.
• Over five years, Total Liabilities peaked at $465.7 million in Q3 2023 and troughed at $262.8 million in Q2 2022.
• A 5-year average of $340.2 million and a median of $336.3 million in 2026 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities slumped 42.61% in 2022, then jumped 71.99% in 2023.
• A 5-year view of Total Liabilities shows it stood at $312.9 million in 2022, then increased by 16.11% to $363.3 million in 2023, then slipped by 10.13% to $326.5 million in 2024, then climbed by 3.71% to $338.6 million in 2025, then retreated by 0.68% to $336.3 million in 2026.
• Business Quant data shows MYGN's Total Liabilities at $336.3 million in Q1 2026, $338.6 million in Q4 2025, and $355.3 million in Q3 2025.